Investors' Soapbox AM

Bristol-Myers Stumble Boosts Gilead, Vertex

The suspension of Bristol-Myers' hepatitis C drug was unexpected.

August 3, 2012

Maxim Group

Bristol-Myers Squibb has suspended study drug administration in the ongoing Phase II study of BMS-986094 for hepatitis C. This news keeps Gilead Sciences in the lead, with Vertex Pharmaceuticals and Idenix Pharmaceuticals as the next in line.

News came out Wednesday evening that Bristol-Myers Squibb (ticker: BMY) has now...